You are not logged in.

ASPREE-D: Aspirin for the prevention of depression in the elderly

Berk, Michael, Woods, R.L., Nelson, M.R., Shah, R.C., Reid, C.M., Storey, E., Fitzgerald, S.M., Lockery, J.E., Wolfe, R., Mohebbi, M., Murray, A.M., Kirpach, B., Grimm, R. and McNeil, J.J. 2016, ASPREE-D: Aspirin for the prevention of depression in the elderly, International psychogeriatrics, vol. 28, no. 10, pp. 1741-1748, doi: 10.1017/S104161021600079X.

Attached Files
Name Description MIMEType Size Downloads

Title ASPREE-D: Aspirin for the prevention of depression in the elderly
Author(s) Berk, MichaelORCID iD for Berk, Michael orcid.org/0000-0002-5554-6946
Woods, R.L.
Nelson, M.R.
Shah, R.C.
Reid, C.M.
Storey, E.
Fitzgerald, S.M.
Lockery, J.E.
Wolfe, R.
Mohebbi, M.
Murray, A.M.
Kirpach, B.
Grimm, R.
McNeil, J.J.
Journal name International psychogeriatrics
Volume number 28
Issue number 10
Start page 1741
End page 1748
Total pages 8
Publisher Cambridge University Press
Place of publication Cambridge, Eng.
Publication date 2016-10
ISSN 1741-203X
Keyword(s) antidepressants
aspirin
biomarkers
depression
immunology
inflammation
prevention
risk
Social Sciences
Science & Technology
Life Sciences & Biomedicine
Psychology, Clinical
Geriatrics & Gerontology
Gerontology
Psychiatry
Psychology
C-REACTIVE PROTEIN
SCALE CES-D
ACETYLSALICYLIC-ACID
MAJOR DEPRESSION
INFLAMMATORY MARKERS
DISORDERS
AUGMENTATION
METAANALYSIS
ASSOCIATION
FLUOXETINE
Summary BACKGROUND: Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention.

METHOD: ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression.

RESULTS: This paper presents the rationale for the study and presents a summary of the study design.

CONCLUSIONS: ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression.
Language eng
DOI 10.1017/S104161021600079X
Field of Research 110319 Psychiatry (incl Psychotherapy)
Socio Economic Objective 920410 Mental Health
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, International Psychogeriatric Association
Persistent URL http://hdl.handle.net/10536/DRO/DU:30090270

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 41 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Fri, 16 Dec 2016, 13:32:00 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.